Carbamazepine (Epilepsy) updated on 04-22-2025

Gestational diabetes

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12675
R47895		 Mari (Carbamazepine), 2022 Gestational diabetes throughout pregnancy retrospective cohort exposed to other treatment, sick Adjustment: No 0.11 [0.00;2.96] C 0/29   1/11 1 29
ref
S8082
R24684		 Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.44 [0.05;40.54] C
excluded (control group) 		1/15   0/7 1 15
ref
S8074
R24632		 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.50 [0.09;26.01] C 1/15   1/22 2 15
ref
Total 2 studies 0.47 [0.04;5.89] 3 44
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mari (Carbamazepine), 2022Mari, 2022 1 0.11[0.00; 2.96]12945%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: unclear Aydin (Carbamazepine) (Controls unexposed, sick), 2020Aydin, 2020 2 1.50[0.09; 26.01]21555%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 27% 0.47[0.04; 5.89]3440.05.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.47[0.04; 5.89]34427%NAMari (Carbamazepine), 2022 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.50[0.09; 26.01]215 -NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 0.11[0.00; 2.96]129 -NAMari (Carbamazepine), 2022 1 Tags Adjustment   - No  - No 0.47[0.04; 5.89]34427%NAMari (Carbamazepine), 2022 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 2 All studiesAll studies 0.47[0.04; 5.89]34427%NAMari (Carbamazepine), 2022 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 20.05.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8082

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.50[0.09; 26.01]215 -NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.39[0.03; 4.86]24413%NAMari (Carbamazepine), 2022 Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 20.510.01.0